研究者業績

西村 基

ニシムラ モトイ  (Nishimura Motoi)

基本情報

所属
千葉大学 医学部附属病院検査部 講師
(兼任)遺伝子診療部 講師
学位
医学博士(2004年3月 千葉大学)

研究者番号
80400969
J-GLOBAL ID
201901001893625153
researchmap会員ID
B000380375

外部リンク

学歴

 1

論文

 123
  • 北村 浩一, 石毛 崇之, 根川 真実, 藤川 樹, 川崎 健治, 西村 基, 松下 一之
    医療検査と自動化 45(4) 449-449 2020年8月  
  • Kentaro Ishikawa, Kenichiro Okimoto, Tomoaki Matsumura, Yosuke Hirotsu, Kenji Amemiya, Takashi Kishimoto, Naoki Akizue, Yuki Ohta, Keiko Saito, Daisuke Maruoka, Motoi Nishimura, Kazuyuki Matsushita, Hitoshi Mochizuki, Makoto Arai, Jun Kato, Osamu Yokosuka, Masao Omata, Naoya Kato
    DIGESTIVE DISEASES AND SCIENCES 2020年8月  査読有り
    Background/Aim Barrett's esophagus (BE) is a precursor of esophageal adenocarcinoma (EAC). Therefore, an accurate diagnosis of BE is important for the subsequent follow-up and early detection of EAC. However, the definitions of BE have not been standardized worldwide; columnar-lined epithelium (CLE) without intestinal metaplasia (IM) and/or < 1 cm is not diagnosed as BE in most countries. This study aimed to clarify the malignant potential of CLE without IM and/or < 1 cm genetically. Method A total of 96 consecutive patients (including nine patients with EAC) who had CLE were examined. Biopsies for CLE were conducted, and patients were divided into those with IM and > 1 cm (Group A) and those without IM and/or < 1 cm (Group B). Malignant potential was assessed using immunochemical staining for p53. Moreover, causative genes were examined using next-generation sequencing (NGS) on ten patients without Helicobacter pylori infection and without atrophic gastritis. Result Of the 96 patients, 66 were in Group B. The proportion of carcinoma/dysplasia in Group A was significantly higher than that in Group B (26.7% in Group A and 1.5% in Group B;p < 0.01). However, one EAC patient was found in Group B. In the immunostaining study for non-EAC patients, an abnormal expression of p53 was not observed in Group A, whereas p53 loss was observed in three patients (4.6%) in Group B. In the NGS study, a TP53 mutation was found in Group B. Conclusion CLE without IM and/or < 1 cm has malignant potential. This result suggests that patients with CLE as well as BE need follow-up.
  • Takayuki Ishige, Shota Murata, Toshibumi Taniguchi, Akiko Miyabe, Kouichi Kitamura, Kenji Kawasaki, Motoi Nishimura, Hidetoshi Igari, Kazuyuki Matsushita
    CLINICA CHIMICA ACTA 507 139-142 2020年8月  査読有り
    Background: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA.Methods: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control.Results: Good correlation of C-q values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (< 25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method.Conclusion: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians.
  • 伊藤 智里, 仙波 利寿, 大山 正之, 古家 若葉, 諫山 拓也, 西村 基, 川崎 健治, 松下 一之
    日本検査血液学会雑誌 21(学術集会) S223-S223 2020年6月  
  • 中津川 智子, 三階 貴文, 楯 真一, 藤本 浩司, 宇津野 恵美, 神津 三佳, 松下 一之, 西村 基, 長嶋 健, 生水 真紀夫, 羽田 明, 野村 文夫, 市川 智彦
    日本遺伝カウンセリング学会誌 41(2) 83-83 2020年6月  
  • 西村 基, 楯 真一, 錦見 恭子, 松岡 歩, 生水 真紀夫, 太和田 暁之, 新井 誠人, 滝口 裕一, 藤木 亮次, 金田 篤志, 宇津野 恵美, 市川 智彦, 太田 昌幸, 松坂 恵介, 佐伯 宏美, 藤澤 陽子, 石毛 崇之, 北村 浩一, 小林 崇平, 中津川 智子, 清水 直美, 松下 一之
    日本遺伝カウンセリング学会誌 41(2) 85-85 2020年6月  
  • 伊藤 智里, 仙波 利寿, 大山 正之, 古家 若葉, 諫山 拓也, 西村 基, 川崎 健治, 松下 一之
    日本検査血液学会雑誌 21(学術集会) S223-S223 2020年6月  
  • Shoko Kakinuma, Minako Beppu, Setsu Sawai, Akitoshi Nakayama, Shigeki Hirano, Yoshitaka Yamanaka, Tatsuya Yamamoto, Chigusa Masafumi, Xiamuxiya Aisihaer, Alimasi Aersilan, Yue Gao, Kenichi Sato, Itoga Sakae, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Satoshi Kuwabara, Tomoaki Tanaka
    eNeurologicalSci 19 100239-100239 2020年6月  査読有り
    Background: Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia. Genetic background, particularly polymorphisms of dopamine metabolism genes, may affect the occurrence of dyskinesia in Parkinson's disease patients. Methods: We investigated polymorphisms of dopamine metabolism genes, including catechol-O-methyltransferase, monoamine oxidase B, dopamine beta-hydroxylasedopamine, dopamine receptors D1, D2, and D3, and dopamine transporter, in 110 patients with Parkinson's disease. Cox proportional hazards regression was used to detect associations between genotypes and levodopa-induced dyskinesia. Results: Monoamine oxidase B rs1799836 was the only polymorphism correlated with risk of dyskinesia. Patients with an AG or GG genotype were more likely to have dyskinesia than those with an AA genotype (adjusted hazard ratio, 3.41; 95% confidence interval, 1.28-9.10). Also, Kaplan-Meier curves demonstrated that patients with an AG or GG genotype developed dyskinesia earlier than those with an AA genotype (log-rank test, p = .004). Conclusions: In Parkinson's disease patients, the monoamine oxidase B rs1799836 G allele is associated with a greater likelihood of developing dyskinesia than the A allele, possibly due to its association with lower monoamine oxidase B activity in the brain. Thus, detection of monoamine oxidase B polymorphisms may be useful for determining the optimal dosing of antiparkinson medications.
  • Atsushi Nakagomi, Fumio Imazeki, Motoi Nishimura, Yuji Sawabe, Kazuyuki Matsushita, Akitoshi Murata, Mariko Watase, Sho Okada, Yoshio Kobayashi
    HYPERTENSION RESEARCH 43(3) 207-212 2020年3月  査読有り
    Isolated systolic hypertension (ISH), defined as systolic blood pressure (SBP) >= 140 mmHg and diastolic BP (DBP) <90 mmHg, is a common type of hypertension among young men. This study aimed to investigate the clinical characteristics, central blood pressure, and arterial stiffness of young and middle-aged Japanese individuals with ISH. A total of 432 male participants, aged 18-49 years, were classified into six subgroups: optimal BP (SBP <120 mmHg and DBP <80 mmHg), high-normal BP (SBP 120-129 mmHg and DBP <80 mmHg), high-BP (SBP 130-139 mmHg and/or DBP 80-89 mmHg), ISH (SBP >= 140 mmHg and DBP <90 mmHg), isolated diastolic hypertension (IDH) (SBP <140 mmHg and DBP >= 90 mmHg), and systolic and diastolic hypertension (SDH) (SBP >= 140 mmHg and DBP >= 90 mmHg). Participants with ISH had a greater body mass index (BMI) and waist circumference than the optimal BP participants but were more likely to be physically active than the IDH and SDH participants. The central SBP of the ISH subgroup was higher than that of the optimal/high-normal/high-BP subgroups and lower than that of the SDH subgroup. The carotid-femoral pulse wave velocity (cfPWV) of the ISH subgroup was higher than that of the optimal and high-normal BP subgroups and lower than that of the SDH subgroup after adjusting for age, heart rate, BMI, and physical activity. These differences disappeared after further adjustment for central mean arterial pressure. In conclusion, the central SBP of Japanese men with ISH was greater than that of Japanese men with optimal/high-normal/high-BP, but the progression of arterial stiffness was unclear.
  • Takayuki Ishige, Sakae Itoga, Kenji Kawasaki, Setsu Sawai, Motoi Nishimura, Fumio Nomura, Kazuyuki Matsushita
    ANALYTICAL BIOCHEMISTRY 587 113448-113448 2019年12月  査読有り
    The multiplex PCR melting analysis method was developed for detecting the five UGT1A1 variants. Multiplexing was achieved using color probes and T-m. The probes for *28/*6, *27, *29, and *7 were discriminated by colors. Although the probes for *28 and *6 had the same colors, their variants were clearly discriminated by probe T-m. The allelic frequencies of each genotype were 0.12 for *28, 0.19 for *6, 0.02 for *27, 0.0 for *29, and 0.005 for *7. We developed a multiplex PCR melting analysis method, which will be useful in molecular diagnostics and pharmacogenetic analyses in clinical laboratories.
  • 別府 美奈子, 澤井 摂, 宇津野 恵美, 内垣 洋祐, 浦尾 充子, 石毛 崇之, 糸賀 栄, 西村 基, 松下 一之, 野村 文夫, 市川 智彦, 桑原 聡, 田中 知明
    臨床神経学 59(Suppl.) S319-S319 2019年11月  
  • Yue Yao, Motoi Nishimura, Kei Murayama, Naomi Kuranobu, Satomi Tojo, Minako Beppu, Takayuki Ishige, Sakae Itoga, Sachio Tsuchida, Masato Mori, Masaki Takayanagi, Masataka Yokoyama, Kazuyuki Yamagata, Yoshihito Kishita, Yasushi Okazaki, Fumio Nomura, Kazuyuki Matsushita, Tomoaki Tanaka
    SCIENTIFIC REPORTS 9(1) 17411-17411 2019年11月  査読有り
    Next-generation sequencing (NGS) is a revolutionary sequencing technology for analyzing genomes. However, preprocessing methods for mitochondrial DNA (mtDNA) sequencing remain complex, and it is required to develop an authenticated preprocessing method. Here, we developed a simple and easy preprocessing method based on isothermal rolling circle mtDNA amplification using commercially available reagents. Isothermal amplification of mtDNA was successfully performed using both nanoliter quantities of plasma directly and 25 ng of total DNA extracted from blood or tissue samples. Prior to mtDNA amplification, it was necessary to treat the extracted total DNA with Exonuclease V, but it was not required to treat plasma. The NGS libraries generated from the amplified mtDNA provided sequencing coverage of the entire human mitochondrial genome. Furthermore, the sequencing results successfully detected heteroplasmy in patient samples, with called mutations and variants matching those from previous, independent, Sanger sequencing analysis. Additionally, a novel single nucleotide variant was detected in a healthy volunteer. The successful analysis of mtDNA using very small samples from patients is likely to be valuable in clinical medicine, as it could reduce patient discomfort by reducing sampling-associated damage to tissues. Overall, the simple and convenient preprocessing method described herein may facilitate the future development of NGS-based clinical and forensic mtDNA tests.
  • Takayuki Ishige, Sakae Itoga, Kenji Kawasaki, Emi Utsuno, Minako Beppu, Setsu Sawai, Motoi Nishimura, Tomohiko Ichikawa, Fumio Nomura, Kazuyuki Matsushita
    CLINICA CHIMICA ACTA 495 562-569 2019年8月  査読有り
    Background: Long-range PCR (LR-PCR) is used to enrich the target regions of the genome. This study aimed to establish the pipeline of targeted gene sequencing using LR-PCR and massively parallel sequencing (MPS).Methods: The 14-kb-long MEFV gene, including the entire coding exons, was selected as a target gene and amplified using LR-PCR. The evaluated analytical factors were as follows: LR-PCR conditions, three types of post-PCR cleanup methods, and two types of MPS library preparation methods.Results: With regard to LR-PCR conditions, Tks Gflex DNA polymerase at 7-min (30-s/kb) annealing/extension with 100-ng genomic DNA input had the highest yield. Regarding post-PCR purification methods, the magnetic beads-based method had high recovery and purity. In the MPS library preparation methods, the ligation-based method had a higher base coverage in the target (94.58%), uniformity of base coverage (99.95%), and target bases with no strand bias (97.40%). The exonic variants determined by Sanger sequencing were detected by both ligation- and transposon-based methods.Conclusions: Various analytical factors were evaluated, and the pipeline of targeted gene sequencing using LR-PCR and MPS was established. These data can enable the optimization of targeted gene sequencing using LR-PCR and MPS in the clinical laboratory.
  • Takayuki Ishige, Mamoru Satoh, Sakae Itoga, Motoi Nishimura, Kazuyuki Matsushita, Fumio Nomura
    CLINICA CHIMICA ACTA 487 126-132 2018年12月  査読有り
  • Hiroshi Ihara, Sachiko Kiuchi, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Mine Yamashita, Isao Kitajima, Naoko Tsugawa, Toshio Okano, Kouichi Hirota, Masakazu Miura, Masayuki Totani, Naotaka Hashizume
    ANNALS OF CLINICAL BIOCHEMISTRY 55(6) 647-656 2018年11月  査読有り
    Background To assess the vitamin D nutritional status, serum total 25-hydroxyvitamin D (25(OH)D) concentration is measured. We used six automated 25(OH)D immunoassays (AIAs) available in Japan and certified by the Vitamin D Standardization Program (VDSP) at the U.S. Center for Disease Control and Prevention to assess the concordance of the assay results.Methods Serum total 25(OH)D concentrations in SRM 972a and 20 serum samples from patients were determined using three liquid chromatography-tandem mass spectrometry (LC-MS/MS) and six AIAs (pilot study), and an additional 110 serum samples were assessed by the six AIAs (surveillance study). The assay bias from the results of LC-MS/MS by Chiba University or consensus values (i.e. average of six AIAs) was estimated using the procedure described in CLSI document EP09-A3.Results LC-MS/MS at Chiba University could completely separate 25(OH)D2, 25(OH)D3 and 3-epi-25(OH)D3, and the observed values including total 25(OH)D in SRM 972a were all within 1<bold>SD of the assigned values</bold>. All AIAs produced results greater than +/- 3<bold>SD</bold>. In the pilot study, four of the six AIAs had an average percentage bias, as estimated by confidence interval (CI), larger than +/- 5% (acceptance criterion in CLSI); the bias converged from -6.5% to 3.2% after adjustment by LC-MS/MS. In the surveillance study, 25(OH)D concentrations in AIAs all adjusted to LC-MS/MS converged within +/- 5% from consensus values. However, some AIAs showed negative or positive bias from the consensus values.Conclusions Current AIAs in Japan continue to lack standardization. Manufacturers should implement quality assurance strategies so that their values more closely align to those of standard reference material 972a.
  • 澤井摂, 澤井摂, 石毛崇之, 北村浩一, 西村基, 糸賀栄, 松下一之
    臨床病理 66(補冊) 213-213 2018年10月15日  
  • Takayuki Ishige, Sakae Itoga, Emi Utsuno, Motoi Nishimura, Masaharu Yoshikawa, Naoya Kato, Kazuyuki Matsushita, Osamu Yokosuka, Fumio Nomura
    JOURNAL OF MEDICAL GENETICS 55(10) 701-704 2018年10月  査読有り
    Background A genetic diagnosis has been rarely performed in benign familial hyperphosphatasaemia, and molecular mechanism largely remains unclear.Objectives We encountered a case with benign familial hyperphosphatasaemia of intestinal alkaline phosphatase (IAP). To elucidate the molecular mechanism, we performed ALPI gene sequencing and in vitro protein expression analysis.Methods ALPI gene was sequenced by long-range PCR and massively parallel sequencing. The soluble and membrane-bound ALP activities of the cultured cell line, transfected with the wild-type or variant-type ALPI gene were analysed by a glycosylphosphatidylinositol (GPI)-cleaving assay.Results We identified a deletion-insertion variant in the C-terminal end of the ALPI gene. This variant causes the attenuation of the hydrophobicity in GPI-anchor signal of IAP. An in vitro GPI-cleaving assay demonstrated that the membrane-bound IAP was greatly decreased, whereas the soluble IAP was increased, in the variant IAP.Conclusions The C-terminal variant in ALPI causes the benign familial hyperphosphatasaemia of IAP by the attenuation of the membrane-binding capability.
  • 石田 晶子, 姚 躍, 宮林 佑衣, 中山 哲俊, 永野 秀和, 橋本 直子, 鈴木 佐和子, 西村 基, 小出 尚史, 木村 伯子, 小笠原 辰樹, 藤井 陽一, 小川 誠司, 田中 知明, 横手 幸太郎
    日本内分泌学会雑誌 94(2) 703-703 2018年9月  
  • Fujiki R, Ikeda M, Yoshida A, Akiko M, Yao Y, Nishimura M, Matsushita K, Ichikawa T, Tanaka T, Morisaki H, Morisaki T, Ohara O
    The Journal of molecular diagnostics : JMD 20(5) 572-582 2018年9月  査読有り
  • Sachio Tsuchida, Mamoru Satoh, Hiroshi Umemura, Kazuyuki Sogawa, Masaki Takiwaki, Takayuki Ishige, Yui Miyabayashi, Yuuya Iwasawa, Sohei Kobayashi, Minako Beppu, Motoi Nishimura, Yoshio Kodera, Kazuyuki Matsushita, Fumio Nomura
    PROTEOMICS CLINICAL APPLICATIONS 12(3) e1700047 2018年5月  査読有り
    PurposeHuman serum and plasma are often used as clinical specimens in proteomics analyses, and peptidome profiling of human serum is a promising tool for identifying novel disease-associated biomarkers. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is widely used for peptidomic biomarker discovery. Careful sample collection and handling are required as either can have a profound impact on serum peptidome patterns, yet the effects of preanalytical variables on serum peptidome profiles have not been completely elucidated. The present study investigated the effects of preanalytical variables, including storage temperature, duration (up to 12 months), and thawing methods, on MALDI-TOF MS-based serum peptidome patterns.Experimental designAliquots of serum samples were pretreated with weak cation exchanger magnetic beads using an automated ClinProtRobot system and then analyzed by MALDI-TOF MS.ResultsA number of significant differences in peak intensities were observed depending on sample processing variables.Conclusions and clinical relevanceThese peaks can be used as sample quality markers to assess the effects of long-term storage on serum peptidome profiles using MALDI-TOF MS.
  • Kiyoko Takane, Keisuke Matsusaka, Satoshi Ota, Masaki Fukuyo, Motoi Nishimura, Eiji Sakai, Kazuyuki Matsushita, Hiroyuki Aburatani, Yukio Nakatani, Hisahiro Matsubara, Kiwamu Akagi, Atsushi Kaneda
    CANCER SCIENCE 109 861-861 2018年1月  
  • Ishige T, Satoh M, Ogawa S, Nishimura M, Matsushita K, Higashi T, Nomura F
    Clinica chimica acta; international journal of clinical chemistry 473 173-179 2017年10月  査読有り
  • Kazuho Ashizawa, Syota Murata, Takashi Terada, Daisuke Ito, Masaru Bunya, Koji Watanabe, Yoko Teruuchi, Sachio Tsuchida, Mamoru Satoh, Motoi Nishimura, Kazuyuki Matsushita, Yuji Sugama, Fumio Nomura
    JOURNAL OF MICROBIOLOGICAL METHODS 139 54-60 2017年8月  査読有り
    Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) can be used to identify pathogens in blood culture samples. However, sample pretreatment is needed for direct identification of microbes in blood culture bottles. Conventional protocols are complex and time-consuming. Therefore, in this study, we developed a method for collecting bacteria using polyallylamine polystyrene copolymer for application in wastewater treatment technology. Using representative bacterial species Escherichia coli and Staphylococcus capitis, we found that polyallylamine polystyrene can form visible aggregates with bacteria, which can be identified using MALDI-TOF MS. The processing time of our protocol was as short as 15 min. Hemoglobin interference in MALDI spectra analysis was significantly decreased in our method compared with the conventional method. In a preliminary experiment, we evaluated the use of our protocol to identify clinical isolates from blood culture bottles. MALDI-TOF MS-based identification of 17 strains from five bacterial species (E. coli, Klebsiella pneumoniae, Enterococcus faecalis, S. aureus, and S. capitis) collected by our protocol was satisfactory. Prospective large-scale studies are needed to further evaluate the clinical application of this novel and simple method of collecting bacteria in blood culture bottles.
  • Motoi Nishimura, Marehiko Ueda, Ryota Ebata, Emi Utsuno, Takuma Ishii, Kazuyuki Matsushita, Osamu Ohara, Naoki Shimojo, Yoshio Kobayashi, Fumio Nomura
    BMC MEDICAL GENETICS 18(1) 66 2017年6月  査読有り
    Background: According to previous KCNQ1 (potassium channel, voltage gated, KQT-like subfamily, member 1) gene screening studies, missense variants, but not nonsense or frame-shift variants, cause the majority of long QT syndrome (LQTS; Romano-Ward syndrome [RWS]) 1 cases. Several missense variants are reported to cause RWS by a dominant-negative mechanism, and some KCNQ1 variants can cause both Jervell and Lange-Nielsen Syndrome (JLNS; in an autosomal recessive manner) and LQTS1 (in an autosomal dominant manner), while other KCNQ1 variants cause only JLNS. The human KCNQ1 gene is known to have two transcript isoforms (kidney isoform and pancreas isoform), and both isoforms can form a functional cardiac potassium channel.Case presentation: Here, we report a novel nonsense KCNQ1 variant causing not only JLNS, but also significant QTc prolongation identical to RWS in an autosomal dominant manner. Our case study supports that haploinsufficiency in the KCNQ1 gene is causative of significant QTc prolongation identical to RWS. Interestingly, the nonsense variant (NM_000218.2:c.115G > T [p.Glu39X]) locates in exon 1a of KCNQ1, which is a kidney-isoform specific exon. The variant is located closer to the N-terminus than previously identified nonsense or frame-shift variants.Conclusion: To the best of our knowledge, this is the first report showing that a nonsense variant in exon 1a of KCNQ1, which is the kidney-isoform specific exon, causes JLNS. Our findings may be informative to the genetic pathogenesis of RWS and JLNS caused by KCNQ1 variants.
  • Somayeh Ahmadloo, Hirofumi Nakaoka, Takahide Hayano, Kazuyoshi Hosomichi, Hua You, Emi Utsuno, Takafumi Sangai, Motoi Nishimura, Kazuyuki Matsushita, Akira Hata, Fumio Nomura, Ituro Inoue
    JOURNAL OF HUMAN GENETICS 62(5) 561-567 2017年5月  査読有り
    Genetic testing for breast cancer predisposing genes, BRCA1 and BRCA2, can take advantage for early identification of carriers with pathogenic germline mutations. However, conventional approaches based on Sanger sequencing are laborious and expensive. Next-generation sequencing technology has a great impact on investigation of medical genomics and now applied clinical genetics. We provide a protocol based on a pool and capture method followed by high-throughput sequencing, which realizes a rapid, high-quality, high-accuracy and low-cost testing for mutations in BRCA1 and BRCA2 by using small amounts of input DNA. Custom capture probes were designed for 195 kb regions encompassing the entire BRCA1 and BRCA2. DNA libraries of 96 samples with distinct indices were pooled before hybridizing to the capture probes, which largely reduced labor and cost. The captured library was run on the Illumina MiSeq sequencer. We applied the method to 384 Japanese individuals including 11 patients with breast cancer whose mutation statuses had been determined by standard clinical testing and 373 individuals from a general population. 99.99% of coding exons and their 20 bp flanking regions were covered with a minimum of 20 reads and the average depth was 179.5, supporting confident variant detection. The sequencing method rendered concordant results for 11 patients with breast cancer compared with the standard clinical testing including nine mutations in eight patients. Among 373 individuals from the general population, novel stop gain and frameshift deletion in BRCA2 were identified, which led to truncated protein and were most likely to be pathogenic. The result suggests the importance of a large-scale population-wide screening for carriers of mutations in these genes.
  • Minako Beppu, Setsu Sawai, Sonoko Misawa, Masahiro Mori, Shoichi Ito, Kazuyuki Sogawa, Motoi Nishimura, Kazuyuki Matsushita, Fumio Nomura, Satoshi Kuwabara
    JOURNAL OF NEUROIMMUNOLOGY 302 20-22 2017年1月  査読有り
    Juvenile muscular atrophy of the distal upper extremity (Hirayama disease) is characterized by adolescent-onset muscular weakness of the distal upper limb. Several studies showed the contribution of atopic disposition and hyperlgEaemia to the disease process, but it has not been well clarified. To identify cytokine and chemokine profiles in Hirayama disease, serum samples were analyzed using multiplex magnetic bead-based assay. Eotaxin, MCP-1 and RANTES levels were significantly higher in Hirayama disease (N = 11) than in normal controls (N = 12). These chemokines are associated with inflammatory cell recruitment. Allergic inflammation may involve in the pathogenesis of Hirayama disease. (C) 2016 Elsevier B.V. All rights reserved.
  • Kiyoko Takane, Keisuke Matsusaka, Satoshi Ota, Masaki Fukuyo, Yao Yue, Motoi Nishimura, Eiji Sakai, Kazuyuki Matsushita, Hideaki Miyauchi, Hiroyuki Aburatani, Yukio Nakatani, Tadatoshi Takayama, Hisahiro Matsubara, Kiwamu Akagi, Atsushi Kaneda
    ONCOTARGET 7(51) 84003-84016 2016年12月  査読有り
    While sporadic colorectal cancer (CRC) is classified into several molecular subtypes, stratification of familial colorectal tumors is yet to be well investigated. We previously established two groups of methylation markers through genome-wide DNA methylation analysis, which classified sporadic CRC and adenoma into three distinct subgroups: high-, intermediate-, and low-methylation epigenotypes. Here, we investigated familial adenomatous polyposis (FAP), through quantitative methylation analysis of 127 samples (16 cancers, 96 adenomas, and 15 benign mucosa from 14 patients with FAP) using six Group-1 and 14 Group-2 methylation markers, APC, BRAF, and KRAS mutation analysis, and CTNNB1 and TP53 immunohistochemical analysis. All the 14 patients presented with APC germline mutation. Three were from the same family and presented the same APC mutation. FAP tumors lacked BRAF-mutation(+) high-methylation epigenotype and were classified into two methylation epigenotypes. While 24 of 112 tumor samples showed intermediate-methylation epigenotype significantly correlating with KRAS-mutation(+) (P= 3x10(-4)), 88 tumor samples showed low-methylation epigenotype correlating with the absence of KRAS- and BRAF-mutations. Similar to sporadic CRC, CTNNB1 was frequently activated at the adenoma stage, and TP53 mutation occurred during cancer development from adenoma. Whereas some patients showed a single epigenotype in all tumors throughout the colon, tumors with two distinct epigenotypes developed within a family with the same APC mutation or even within one patient. Methylation accumulation significantly correlated with proximal location and older age. These results indicate that there are at least two distinct molecular subtypes of FAP tumors, resembling sporadic CRC and independent from the APC germline mutation status.
  • Mamoru Satoh, Takayuki Ishige, Shoujiro Ogawa, Motoi Nishimura, Kazuyuki Matsushita, Tatsuya Higashi, Fumio Nomura
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY 408(27) 7617-7627 2016年11月  査読有り
    The quantification of serum 25-hydroxyvitamin D [25(OH)D] as an indicator of vitamin D status is currently primarily conducted by immunoassays, yet LC-MS/MS would allow more accurate determination. Furthermore, LC-MS/MS would allow simultaneous measurement of multiple analytes. The aim of this study was to develop and validate an LC-MS/MS method to simultaneously measure four vitamin D metabolites (25(OH)D-3, 3-epi-25(OH)D-3, 25(OH)D-2, and 24,25(OH)(2)D-3) in serum for clinical laboratory applications. Serum samples were first prepared in a 96-well supported liquid extraction plate and the eluate was derivatized using the Cookson-type reagent 4-(4'-dimethylaminophenyl)-1,2,4-triazoline-3,5-dione (DAPTAD), which rapidly and quantitatively reacts with the s-cis-diene structure of vitamin D metabolites. The derivatized samples were subjected to LC-MS/MS, ionized by electrospray ionization (positive-ion mode), and detected by selected reaction monitoring. The lower limits of quantification for 25(OH)D-3, 3-epi-25(OH)D-3, 25(OH)D-2, and 24,25(OH)(2)D-3 were 0.091, 0.020, 0.013, and 0.024 ng/mL, respectively. The accuracy values and the extraction recoveries for these four metabolites were satisfactory. Serum 25(OH)D levels determined by our LC-MS/MS were compared with those obtained by conventional radioimmunoassay (RIA) that cannot distinguish 25(OH)D-3 and 25(OH)D-2. The values obtained by the RIA method exhibited a mean bias of about 8.35 ng/mL, most likely as a result of cross reaction of the antibody with low-abundance metabolites, including 24,25(OH)(2)D-3. Various preanalytical factors, such as long sample sitting prior to serum separation, repeated freeze-thaw cycles, and the presence of anticoagulants, had no significant effects on these determinations. This high-throughput LC-MS/MS simultaneous assay of the four vitamin D metabolites 25(OH)D-3, 3-epi-25(OH)D-3, 25(OH)D-2, and 24,25(OH)(2)D-3 required as little as 20 mu L serum. This method will aid further understanding of low-abundance vitamin D metabolites, as well as the accurate determination of 25(OH)D-3 and 25(OH)D-2.
  • Kikuchi W, Nishimura M, Kuga T, Tsuchida S, Saito T, Satoh M, Noda K, Kodera Y, Tomonaga T, Nomura F
    Clinical proteomics 13 27 2016年10月  査読有り
  • 松下 一之, 西村 基, 糸賀 栄, 石毛 崇之, 北村 浩一, 別府 美奈子, 堤 正好, 古田 耕, 澤部 祐司, 野村 文夫
    日本臨床検査自動化学会会誌 41(3) 299-307 2016年6月  
  • Sachio Tsuchida, Mamoru Satoh, Masaki Takiwaki, Michiru Wakabayashi, Takayuki Ishige, Minako Beppu, Motoi Nishimura, Kazuyuki Matsushita, Fumio Nomura
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS 22(2) 249-253 2016年6月  査読有り
    Periodontal disease is an inflammatory disease caused by gram-negative bacteria, such as Porphyromonas gingivalis and Actinobacllus actinomycetemcomitans. Antimicrobial peptides kill organisms, such as gram-negative and gram-positive bacteria, mycobacteria, enveloped viruses, and fungi. We previously identified the antimicrobial peptide dermcidin (DCD) in the gingival crevicular fluid (GCF) using proteomic analyses. Moreover, western blot analysis revealed that the molecular weights of GCF protein bands considerably varied (approximately 27 kDa). We attempted to explore the considerable variation in the molecular weights of protein bands using on-membrane digestion and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses. We examined ubiquitin among the DCD-interacting proteins. In immunoprecipitation experiments, ubiquitinated DCD was detected by western blotting and by immunoprecipitation with an antibody against DCD and mono- or poly-ubiquitinated proteins. These analyses indicated the possible involvement of the ubiquitination reaction. Ubiquitinated DCD may protect against periodontal bacterial pathogen invasion in GCF.
  • Takeshi Nishi, Hiroyuki Takaoka, Nobusada Funabashi, Motoi Nishimura, Osamu Ohara, Takeru Makiyama, Marehiko Ueda, Takatsugu Kajiyama, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 209 248-252 2016年4月  査読有り
  • Takayuki Ishige, Motoi Nishimura, Mamoru Satoh, Mai Fujimoto, Masaki Fukuyo, Toshihisa Semba, Sayaka Kado, Sachio Tsuchida, Setsu Sawai, Kazuyuki Matsushita, Akira Togawa, Hisahiro Matsubara, Atsushi Kaneda, Fumio Nomura
    SCIENTIFIC REPORTS 6 21681 2016年2月  査読有り
    Gastric cancer is classified into two subtypes, diffuse and intestinal. The diffuse-type gastric cancer (DGC) has poorer prognosis, and the molecular pathology is not yet fully understood. The purpose of this study was to identify functional secreted molecules involved in DGC progression. We integrated the secretomics of six gastric cancer cell lines and gene expression analysis of gastric cancer tissues with publicly available microarray data. Hierarchical clustering revealed characteristic gene expression differences between diffuse- and intestinal-types. GDF15 was selected as a functional secreted molecule owing to high expression only in fetal tissues. Protein expression of GDF15 was higher in DGC cell lines and tissues. Serum levels of GDF15 were significant higher in DGC patients as compared with healthy individuals and chronic gastritis patients, and positively correlated with wall invasion and lymph node metastasis. In addition, the stimulation of GDF15 on NIH3T3 fibroblast enhanced proliferation and up-regulated expression of extracellular matrix genes, which were similar to TGF-beta stimulation. These results indicate that GDF15 contributes to fibroblast activation. In conclusion, this study revealed that GDF15 may be a novel functional secreted molecule for DGC progression, possibly having important roles for cancer progression via the affecting fibroblast function, as well as TGF-beta.
  • Kitamura K, Matsushita K, Kobayashi S, Ishige T, Semba T, Kimura A, Kazami T, Ohyama M, Itoga S, Beppu M, Nishimura M, Satoh M, Nomura F
    Rinsho byori. The Japanese journal of clinical pathology 63(9) 1091-1102 2015年9月  査読有り
  • 石毛 崇之, 佐藤 守, 小川 祥二郎, 西村 基, 東 達也, 野村 文夫
    臨床病理 63(4) 457-464 2015年4月  査読有り
  • Nishimura M, Nomura F
    Nihon rinsho. Japanese journal of clinical medicine 73(4) 587-600 2015年4月  査読有り
  • Takayuki Ishige, Mamoru Satoh, Shoujiro Ogawa, Motoi Nishimura, Tatsuya Higashi, Fumio Nomura
    Rinsho byori. The Japanese journal of clinical pathology 63(4) 457-64 2015年4月  査読有り
    Vitamin D is pro-hormone that has important roles in calcium metabolism in the intestine, kidneys, and bone. Many studies have indicated that vitamin D deficiency causes not only rickets and osteomalacia, but also increases the risk of various diseases such as cancer and autoimmune disease. Of the many vitamin D metabolites, 25-hydroxyvitamin D[25OH-D], 1α,25-dihydroxyvitamin D[1,25(OH)2-D], and 24,25-dihydroxyvitamin D [24,25 (OH) 2-D] are important for assessing vitamin D metabolism. They are circulating, biologically active, and major inactive forms of vitamin D metabolite, respectively. Immunoassays are widely used for the measurement of serum/plasma vitamin D metabolites. With such an assay, however, the accurate quantification of these metabolites is difficult because of cross-reactivity. Liquid chromatography-tandem mass spectrometry [LC-MS/MS] is the gold standard method for analyzing these metabolites due to its high sensitivity and selectivity. Derivatization with a Cookson-type reagent is a key technique for robust and sensitive analysis by LC-MS/MS. A Cookson-type reagent rapidly and quantitatively reacts with the s-cis-diene structure of vitamin D metabolites, and markedly enhances the ionization efficiency. Using a recently developed Cookson-type reagent (DAPTAD), we successfully established an LC-MS/MS-based method for analyzing serum vitamin D metabolites including 250H-D, 1,25 (OH) 2-D, and 24,25 (OH) 2-D. Thus, LC-MS/MS can be a powerful tool for the accurate determination of vitamin D metabolism. In this review, we describe the advantages of LC-MS/MS for the determination of vitamin D metabolites.
  • Sachio Tsuchida, Mamoru Satoh, Kazuyuki Sogawa, Yusuke Kawashima, Sayaka Kado, Takayuki Ishige, Minako Beppu, Setsu Sawai, Motoi Nishimura, Yoshio Kodera, Kazuyuki Matsushita, Fumio Nomura
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 119(3) e208 2015年3月  査読有り
  • 松下 一之, 糸賀 栄, 西村 基
    臨床病理 : 日本臨床検査医学会誌 63(3) 347-360 2015年3月  査読有り
  • Shunsuke Segawa, Motoi Nishimura, Kazuyuki Sogawa, Sachio Tsuchida, Shota Murata, Masaharu Watanabe, Kazuyuki Matsushita, Katsuhiko Kamei, Fumio Nomura
    CLINICAL PROTEOMICS 12(1) 6 2015年3月  査読有り
    Background: The MALDI (matrix-assisted laser desorption/ionization) Biotyper system for bacterial identification has already been utilized in clinical microbiology laboratories as a successful clinical application of protoemics. However, in cases of Nocardia, mass spectra suitable for MALDI Biotyper identification are often not obtained if such specimens are processed like general bacteria. This problem is related to the insufficiencies in bacterial spectrum databases that preclude accurate specimen identification. Here, we developed a bacterial processing method to improve mass spectra from specimens of the genus Nocardia. In addition, with the new processing method, we constructed a novel in-house bacterial database that combines a commercial database and mass spectra of Nocardia strains from the Department of Clinical Laboratory at Chiba University Hospital (DCLC) and the Medical Mycology Research Center at Chiba University (MMRC).Results: The newly developed method (Nocardia Extraction Method at DCLC [NECLC]) based on ethanol-formic acid extraction (EFAE) improved mass spectra obtained from Nocardia specimens. The Nocardia in-house database at Chiba University Hospital (NDCUH) was then successfully validated. In brief, prior to introduction of the NECLC and NDCUH, 10 of 64 (15.6%) clinical isolates were identified at the species level and 16 isolates (25.0%) could only be identified at the genus level. In contrast, after the introduction, 58 isolates (90.6%) were identified at the species level and 6 isolates (9.4%) were identified at the genus level.Conclusions: The results of this study suggest that MALDI-TOF (time-of-flight) Biotyper system can identify Nocardia accurately in a short time in combination with a simple processing method and an in-house database.
  • 瀬川 俊介, 西村 基, 曽川 一幸, 村田 正太, 齊藤 知子, 宮部 安規子, 佐海 知子, 上原 麻美, 中村 恵海, 渡邊 正治, 亀井 克彦, 野村 文夫
    日本臨床微生物学雑誌 25(Suppl.1) 254-254 2014年12月  
  • Tsuchida S, Satoh M, Sogawa K, Ishige T, Segawa S, Kado S, Rahmutulla B, Ogita M, Sawai S, Beppu M, Nishimura M, Aoki A, Kodera Y, Matsushita K, Izumi Y, Nomura F
    Journal of Proteomics & Bioinformmatics 7(12) 379-384 2014年12月  査読有り
  • Takayuki Ishige, Sakae Itoga, Kenichi Sato, Kouichi Kitamura, Motoi Nishimura, Setsu Sawai, Kazuyuki Matsushita, Kazufumi Suzuki, Satoshi Ota, Hideaki Miyauchi, Hisahiro Matsubara, Yukio Nakatani, Fumio Nomura
    CLINICAL BIOCHEMISTRY 47(18) 340-343 2014年12月  査読有り
    Objectives: Recent studies have demonstrated that, in advanced colorectal carcinoma (CRC) patients, extended RAS (in KRAS exons 2-4 and NRAS exons 2-4) and BRAF mutations are negative predictors for anti-EGFR treatment efficacy and negative prognostic factor, respectively. Thus, high-throughput and cost-effective methods for identification of the mutation status are required.Design and methods: We developed a PCR-high-resolution melting (HRM)-based method for screening extended RAS and BRAF mutations, and relative frequency of mutations in formalin-fixed paraffin-embedded samples of CRC was analyzed.Results: Among 93 CRC samples, 29 harbored mutations in KRAS exon 2, and 9 harbored mutations in BRAF exon 15. Analysis of 55 KRAS exon 2 and BRAF exon 15 wild-type CRC samples identified the following mutations: 1/55 in exon 3 and 2/55 in exon 4 of KRAS; 1/55 in exon 2, 3/55 in exon 3, and 0/55 in exon 4 of NRAS.Conclusions: Our PCR-HRM method will enable rapid determination of the extended RAS and BRAF mutation status prior to anti-EGFR treatment in the clinical setting. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
  • 芦澤 一穂, 野田 健太, 村田 正太, 宮部 安規子, 瀬川 俊介, 西村 基, 野村 文夫
    日本臨床検査自動化学会会誌 39(4) 511-511 2014年9月  
  • Shunsuke Segawa, Setsu Sawai, Shota Murata, Motoi Nishimura, Minako Beppu, Kazuyuld Sogawa, Masaharu Watanabe, Mamoru Satoh, Tomoo Matsutani, Masayoshi Kobayashi, Yasuo Iwadate, Satoshi Kuwabara, Naokatsu Saeki, Fumio Nomura
    CLINICA CHIMICA ACTA 435 59-61 2014年8月  査読有り
    Background: Bacterial meningitis is a neurological emergency. Early diagnosis and rapid initiation of antimicrobial therapy are vital.Methods: Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) is increasingly used as a rapid and accurate microbial diagnostic method for species identification of pathogens. Although this technology requires a growth step to obtain bacterial colonies for the acquisition of substantial spectra in most cases, it can also be used to analyze clinical specimens such as urine and cerebrospinal fluid for direct bacterial identification. There are very few reports describing the use of MALDI-TOF MS for the direct detection of microorganisms causing bacterial meningitis.Results: We describe a case of bacterial meningitis caused by Klebsiella pneumoniae in which MALDI-TOF MS provided a rapid bacteriological diagnosis, thus enabling early and appropriate treatment.Conclusions: Identification of microbes based on MALDI-TOF MS is now an important technology in clinical microbiology laboratories that are required to provide a rapid diagnosis of bacterial meningitis. (C) 2014 Elsevier B.V. All rights reserved.
  • Kyoji Okita, Nobuhisa Kanahara, Motoi Nishimura, Toshihiko Yoshida, Norio Yasui-Furukori, Tomihisa Niitsu, Taisuke Yoshida, Masatomo Ishikawa, Hiroshi Kimura, Fumio Nomura, Masaomi Iyo
    SCHIZOPHRENIA RESEARCH 157(1-3) 137-141 2014年8月  査読有り
    Accumulating evidence suggests that patients with schizophrenia are exposed to a high risk of osteoporosis/osteopenia caused by long-term antipsychotic treatment. The degree of bone mineral density (BMD) loss that a given antipsychotic may cause is not known. Examinations using a bone turnover marker may more accurately predict the ongoing bone states in psychiatric patients. We measured prolactin, estradiol, testosterone, and bone resorption marker (TRACP-5b) levels in 167 patients with schizophrenia and 60 normal controls. The patients showed significantly higher levels of prolactin and lower levels of TRACP-5b compared to the controls. Moreover, prolactin was negatively correlated with estradiol and testosterone in the group of all male subjects and the male patients. TRACP-5b was positively correlated with prolactin in the female patients and negatively correlated with estradiol in the group of all female subjects. The results show that the bone resorption rate was rather attenuated in the patients compared to the normal controls, suggesting a complicated etiology of BMD loss in schizophrenia patients. Several meaningful correlations between key factors in this study confirmed that hyperprolactinemia induced the suppression of sex hormones, and possibly led to the higher bone turnover. These results indicate that measurement of the resorption marker TRACP-5b might be useful to clarify the pathology of BMD loss. (C) 2014 Elsevier B.V. All rights reserved.
  • Motoi Nishimura, Mamoru Satoh, Kazuyuki Matsushita, Fumio Nomura
    EXPERT REVIEW OF PROTEOMICS 11(4) 405-407 2014年8月  査読有り
    Humans have three major apolipoprotein E (ApoE) alleles (APOE; ε2, ε3 and ε4) that produce three ApoE protein isoforms. The ε2 allele encodes the ApoE2 isoform (Cys112, Cys158), whereas ε3 encodes the wild-type ApoE3 isoform (Cys112, Arg158) and ε4 encodes the ApoE4 isoform (Arg112, Arg158). Because the type of ApoE expressed is related to sporadic Alzheimer's disease risk and familial hyperlipidemia, many clinical studies have utilized ApoE typing in recent years. ApoE serotyping is based on the correlation between ApoE genotype and isoform; it is therefore possible to determine the genotype from the blood ApoE isoform combination. Serotyping ApoE using mass spectrometry promises highly accurate results while requiring minimal amounts of blood and reagents, resulting in lower costs, which suggest that proteomic-based ApoE serotyping may eventually become a routine clinical laboratory test. Not limited to ApoE, proteomic analysis of human samples could be used to intentionally determine-and perhaps unintentionally reveal-personal genetic information. © 2014 Informa UK, Ltd.
  • Sachio Tsuchida, Mamoru Satoh, Kazuyuki Sogawa, Yusuke Kawashima, Sayaka Kado, Takayuki Ishige, Minako Beppu, Setsu Sawai, Motoi Nishimura, Yoshio Kodera, Kazuyuki Matsushita, Fumio Nomura
    PROTEOMICS CLINICAL APPLICATIONS 8(3-4) 232-240 2014年4月  査読有り
    Periodontal disease is a bacterial infection that destroys the gingiva and surrounding tissues of the oral cavity. In recent years, studies have shown a definite association between periodontal disease and other inflammatory conditions of the body. High-throughput analysis of proteins has become possible with the development of MS technology. This breakthrough in proteome technology enables comparative studies of comprehensive protein expression and identification of protein. In case of periodontal disease, proteome analysis using 2DE, as well as gel-free methods, has been reported. As a fluid lying in close proximity to periodontal tissue, the gingival crevicular fluid (GCF) is the principal target in the search for biomarkers of periodontal disease, because its protein composition may reflect the disease pathophysiology. Biochemical marker analysis of GCF is effective for objective diagnosis in the early and advanced stages of periodontal disease. Increasing numbers of recent reports have provided evidence that the proteomic approach is a promising tool for the discovery and identification of biochemical markers of periodontal disease. This search is of continuing interest in the field of experimental and clinical periodontal disease research. In this article, we summarize recent comprehensive proteomic studies aimed at discovering and identifying biomarkers of periodontal disease in GCF.
  • Motoi Nishimura, Mamoru Satoh, Satomi Nishimura, Shoko Kakinuma, Kenichi Sato, Setsu Sawai, Sachio Tsuchida, Takeshi Kazama, Kazuyuki Matsushita, Sayaka Kado, Yoshio Kodera, Fumio Nomura
    PLOS ONE 9(1) e85356 2014年1月  査読有り
    Background: Apolipoprotein E (ApoE) typing is considered important because of the association between ApoE and Alzheimer's disease and familial dyslipidemia and is currently performed by genetic testing (APOE genotyping). ApoE levels in plasma and serum are clinically determined by immunoassay.Methods: Combining an ApoE immunoassay reagent with proteomic analysis using an Orbitrap mass spectrometer, we attempted to resequence ApoE from trace amounts of serum for typing (serotyping). Most (24 of 33) ApoE mutant proteins registered to date with Online Mendelian Inheritance in Man, such as ApoE2 and ApoE4, involve lysine and arginine mutations. Digestion of mutant ApoE with trypsin will thus result in fragments that differ substantially from wild-type ApoE3 in terms of mass, making serotyping ideally suited to mass spectrometry analysis.Results: The mean coverage of the amino acid sequence of full-length ApoE was 91.6% in the protein resequence. Residues 112 and 158 (which are mutated in ApoE2 and ApoE4) were covered in all samples, and the protein sequences were used for serotyping. Serotypes including all heterozygous combinations (ApoE2/E3, E2/E4, E3/E4) corresponded exactly to the APOE genotyping results in each of the subjects.Conclusion: Our novel ApoE serotyping method with protein resequencing requires no synthesis of stable isotope-labeled peptides or genome analysis. The method can use residual blood from samples collected for routine clinical tests, thus enabling retrospective studies with preserved body fluids. The test could be applied to samples from subjects whose DNA is unavailable. In future studies, we hope to demonstrate the capability of our method to detect rare ApoE mutations.
  • 瀬川 俊介, 西村 基, 曽川 一幸, 村田 正太, 齊藤 知子, 宮部 安規子, 佐海 知子, 上原 麻美, 渡邊 正治, 亀井 克彦, 野村 文夫
    JSBMS Letters 38(Suppl.) 51-52 2013年8月  

MISC

 175

共同研究・競争的資金等の研究課題

 17